EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway Programme

Virtual Event, Worldwide

21 - 22 February 2023



Scientific Programme

Tuesday 21st February 2023

Listed times are in Central European Time (CET)

13:00 WELCOME TO DAY ONE

Rene Bernards & Marisol Soengas

SESSION 1: SIGNALLING

Chairs: Marco Hofmann & Anna Obenauf

13:05 Marco Hofmann

Boehringer Ingelheim, Austria

"SOS1i combinations enhance the anti-tumor response and overcome resistance"

Q&A 13:25-13:40

13:40 Chiara Ambrogio

University of Torino, Italy

"Signaling plasticity in pre-clinical models of adaptive and acquired resistance to KRAS-G12C inhibitors"

Q&A 14:00-14:15

14:15 Sara Mainardi

Netherlands Cancer Institute, Netherlands

Proffered Paper 1: "From bench to bedside and back to bench: identification of potential resistance markers for the SHERPA (SHP2 and ERK inhibition in pancreatic cancer) trial."

Q&A 14:25-14:30

14:30 PROGRAMME BREAK

14:45 Frank McCormick

UC San Francisco, USA

"Targeting KRAS and its immediate effectors"

Q&A 15:05-15:20

15:20 Kevan Shokat

UC San Francisco, USA

"Drugging undruggable targets in cancer"

Q&A 15:40-15:55

15:55 PROGRAMME BREAK

SESSION 2: IMMUNE REGULATION

Chairs: Marisol Soengas & Ralph Neumueller

16:10 Caroline Robert

Gustave Roussy, France

"Melanoma Persitent cells: Can we track the invisible?"

Q&A 16:30-16:45

16:45 Roger Lo

UCLA, USA

'Stabilizing the Genome to Prevent Acquired MAPK Inhibitor Resistance'

Q&A 17:05-17:20

17:20 POSTER SPOTLIGHTS

3 top abstracts presented as 3-minute flash talks

17:30 END OF DAY 1 WEBINAR

Once the Webinar has ended we will take a 15-minute break before we begin our Virtual Poster Discussion Session 1

17:45 VIRTUAL POSTER DISCUSSION SESSION 1

An informal and interactive 'virtual' opportunity for participants to browse the posters and make new connections. This 60-minute session will be delivered through the Zoom Meeting platform.

18:45 END OF DAY ONE

Wednesday 22nd February 2023

Listed times are in Central European Time (CET)

13:00 VIRTUAL POSTER DISCUSSION SESSION 2

An informal and interactive 'virtual' opportunity for participants to browse the posters and make new connections. This 60-minute session will be delivered through the Zoom Meeting platform.

14:00 10-minute transition break (Meeting to Webinar)

14:10 WELCOME TO DAY TWO

SESSION 3: RESISTANCE

Chairs: Marco Hofmann & Ralph Neumuller

14:15 Antreas Hindoyan

Amgen Inc

"Putative mechanisms of acquired resistance to sotorasib in KRAS p.G12C-mutated NSCLC and CRC: plasma biomarker analysis of CodeBreaK 100"

Q&A 14:35-14:50

14:50 Paolo Armando Gagliardi

Institute of Cell Biology, Switzerland

Proffered Paper 2: "Targeting apoptosis-induced collective MAPK activity waves to improve breast cancer therapy"

Q&A 15:00-15:05

15:05 Fernando Calvo Baltanas

University of Seville, Spain

Proffered Paper 3: "Validation of SOS1/2 RASGEFs as therapeutic targets in KRASG12D-driven lung adenocarcinoma"

Q&A 15:15-15:20

15:20 PROGRAMME BREAK

15:35 Anna Obenauf

Research Institute of Molecular Pathology, Austria

"Towards rational combination therapies: Understanding tumor evolution during therapy response and resistance"

Q&A 15:55-16:10

16:10 Rene Bernards

The Netherlands Cancer Institute, Netherlands

"Paradoxical activation of oncogenic signaling as a cancer treatment strategy"

Q&A 16:30-16:45

16:45 **Julian Downward**

Francis Crick Institute, UK

"KRAS oncogene signalling and the tumour immune microenvironment in lung cancer"

Q&A 17:05-17:20

17:20 SUMMARY AND END OF DAY TWO

Rene Bernards & Anna Obenauf